Cargando…
Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review
RATIONALE: Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare tumor, with no established standard treatment. Overexpression of vascular endothelial growth factor receptor 2 (VEGFR-2) has been reported in some P-EHE patients. Apatinib, a new small molecule tyrosine kinase inhibitor that spe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Wolters Kluwer Health
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690741/ https://www.ncbi.nlm.nih.gov/pubmed/29137048 http://dx.doi.org/10.1097/MD.0000000000008507 |
_version_ | 1783279671394172928 |
---|---|
author | Zheng, Zhipeng Wang, Hanying Jiang, Hanliang Chen, Enguo Zhang, Jun Xie, Xinyou |
author_facet | Zheng, Zhipeng Wang, Hanying Jiang, Hanliang Chen, Enguo Zhang, Jun Xie, Xinyou |
author_sort | Zheng, Zhipeng |
collection | PubMed |
description | RATIONALE: Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare tumor, with no established standard treatment. Overexpression of vascular endothelial growth factor receptor 2 (VEGFR-2) has been reported in some P-EHE patients. Apatinib, a new small molecule tyrosine kinase inhibitor that specifically targets VEGFR-2, has therapeutic benefits in some advanced tumors. However, its efficacy in P-EHE cases has not been reported. PATIENT CONCERNS: Herein, we presented a 44-year-old man with recurrent hemoptysis for approximately 9 years. DIAGNOSES: After hospitalization, relevant examinations were conducted. The disease was subsequently diagnosed as P-EHE. INTERVENTIONS: The patient underwent pulmonary lobectomy, but subsequently developed multiple metastases. Within the tumor, CD31, CK, and Vimentin were found to be positive, while CD34 was negative. Apatinib was initially administered 250 mg daily doses and after 1 month was increased to 500 mg daily. OUTCOMES: He showed noticeable symptomatic improvements and positive imaging changes in the first month of treatment. However, the disease progressed in the following month, despite the increased apatinib dose. LESSONS: Apatinib is possibly a new treatment for P-EHE. However, further clinical trials are necessary to confirm an effective dose and the efficacy and safety of apatinib in P-EHE treatment. |
format | Online Article Text |
id | pubmed-5690741 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Wolters Kluwer Health |
record_format | MEDLINE/PubMed |
spelling | pubmed-56907412017-11-28 Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review Zheng, Zhipeng Wang, Hanying Jiang, Hanliang Chen, Enguo Zhang, Jun Xie, Xinyou Medicine (Baltimore) 5700 RATIONALE: Pulmonary epithelioid hemangioendothelioma (P-EHE) is a rare tumor, with no established standard treatment. Overexpression of vascular endothelial growth factor receptor 2 (VEGFR-2) has been reported in some P-EHE patients. Apatinib, a new small molecule tyrosine kinase inhibitor that specifically targets VEGFR-2, has therapeutic benefits in some advanced tumors. However, its efficacy in P-EHE cases has not been reported. PATIENT CONCERNS: Herein, we presented a 44-year-old man with recurrent hemoptysis for approximately 9 years. DIAGNOSES: After hospitalization, relevant examinations were conducted. The disease was subsequently diagnosed as P-EHE. INTERVENTIONS: The patient underwent pulmonary lobectomy, but subsequently developed multiple metastases. Within the tumor, CD31, CK, and Vimentin were found to be positive, while CD34 was negative. Apatinib was initially administered 250 mg daily doses and after 1 month was increased to 500 mg daily. OUTCOMES: He showed noticeable symptomatic improvements and positive imaging changes in the first month of treatment. However, the disease progressed in the following month, despite the increased apatinib dose. LESSONS: Apatinib is possibly a new treatment for P-EHE. However, further clinical trials are necessary to confirm an effective dose and the efficacy and safety of apatinib in P-EHE treatment. Wolters Kluwer Health 2017-11-10 /pmc/articles/PMC5690741/ /pubmed/29137048 http://dx.doi.org/10.1097/MD.0000000000008507 Text en Copyright © 2017 the Author(s). Published by Wolters Kluwer Health, Inc. http://creativecommons.org/licenses/by-nd/4.0 This is an open access article distributed under the Creative Commons Attribution-NoDerivatives License 4.0, which allows for redistribution, commercial and non-commercial, as long as it is passed along unchanged and in whole, with credit to the author. http://creativecommons.org/licenses/by-nd/4.0 |
spellingShingle | 5700 Zheng, Zhipeng Wang, Hanying Jiang, Hanliang Chen, Enguo Zhang, Jun Xie, Xinyou Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review |
title | Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review |
title_full | Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review |
title_fullStr | Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review |
title_full_unstemmed | Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review |
title_short | Apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: A case report and literature review |
title_sort | apatinib for the treatment of pulmonary epithelioid hemangioendothelioma: a case report and literature review |
topic | 5700 |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690741/ https://www.ncbi.nlm.nih.gov/pubmed/29137048 http://dx.doi.org/10.1097/MD.0000000000008507 |
work_keys_str_mv | AT zhengzhipeng apatinibforthetreatmentofpulmonaryepithelioidhemangioendotheliomaacasereportandliteraturereview AT wanghanying apatinibforthetreatmentofpulmonaryepithelioidhemangioendotheliomaacasereportandliteraturereview AT jianghanliang apatinibforthetreatmentofpulmonaryepithelioidhemangioendotheliomaacasereportandliteraturereview AT chenenguo apatinibforthetreatmentofpulmonaryepithelioidhemangioendotheliomaacasereportandliteraturereview AT zhangjun apatinibforthetreatmentofpulmonaryepithelioidhemangioendotheliomaacasereportandliteraturereview AT xiexinyou apatinibforthetreatmentofpulmonaryepithelioidhemangioendotheliomaacasereportandliteraturereview |